---
layout: default
title: Milrinone
description: "Milrinone çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚æ¨¡å‹é æ¸¬ç­‰ç´š L5ï¼ŒåŒ…å« 10 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: åƒ…æ¨¡å‹é æ¸¬ (L5)
nav_order: 106
evidence_level: L5
indication_count: 10
---

# Milrinone

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L5</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>10</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Milrinone è—¥å¸«ç­†è¨˜

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Milrinone å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Milrinone æ˜¯ä¸€ç¨®ç£·é…¸äºŒé…¯é…¶æŠ‘åˆ¶åŠ‘ï¼ŒTxGNN é æ¸¬å…¶å°ç¦¿é«®ç—‡åŠé ­ç—›éšœç¤™æœ‰æ½›åŠ›ï¼Œå…¶ä¸­é ­ç—›éšœç¤™ï¼ˆç‰¹åˆ¥æ˜¯å¯é€†æ€§è…¦è¡€ç®¡æ”¶ç¸®ç—‡å€™ç¾¤ç›¸é—œé ­ç—›ï¼‰å·²æœ‰ç—…ä¾‹å ±å‘Šæ”¯æŒå‹•è„ˆå…§ Milrinone çš„ç™‚æ•ˆã€‚
</p>


---

## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| è—¥ç‰©åç¨± | Milrinoneï¼ˆç±³åŠ›å¿ƒï¼‰ |
| DrugBank ID | DB00235 |
| å°ç£å•†å“å | ç±³åŠ›å¿ƒæ³¨å°„åŠ‘0.2æ¯«å…‹/æ¯«å‡ |
| åŸæ ¸å‡†é©æ‡‰ç—‡ | å……è¡€æ€§å¿ƒè¡°ç«­çš„çŸ­æœŸç™‚æ³• |
| é æ¸¬æ–°é©æ‡‰ç—‡ | alopeciaã€hypotrichosis simplex of the scalpã€congenital hypotrichosis miliaã€diffuse alopecia areataã€headache disorderã€congestive heart failureã€migraine disorderã€migraine with brainstem auraã€trigeminal autonomic cephalalgiaã€acute pulmonary heart disease |
| æœ€é«˜é æ¸¬åˆ†æ•¸ | 0.9991ï¼ˆç¦¿é«®ç—‡ï¼‰ |
| è­‰æ“šç­‰ç´š | L3ï¼ˆè§€å¯Ÿæ€§ç ”ç©¶/ç—…ä¾‹å ±å‘Š - é ­ç—›éšœç¤™ï¼‰ |

---


## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. alopecia</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.91%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content" markdown="1">

### ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ

### è—¥ç†æ©Ÿè½‰åˆ†æ

Milrinone æ˜¯é¸æ“‡æ€§ç£·é…¸äºŒé…¯é…¶-3ï¼ˆPDE3ï¼‰æŠ‘åˆ¶åŠ‘ï¼Œé€éå¢åŠ ç´°èƒå…§ cAMP æ¿ƒåº¦ç™¼æ®ä½œç”¨ã€‚å…¶æ©Ÿè½‰èˆ‡é æ¸¬é©æ‡‰ç—‡çš„é—œè¯ï¼š

1. **ç¦¿é«®ç—‡/æ¯›é«®ç¨€ç–ç—‡**ï¼ˆTxGNN Score: 0.9991ï¼‰
   - PDE æŠ‘åˆ¶åŠ‘ï¼ˆå¦‚ minoxidilï¼‰å·²çŸ¥å¯ä¿ƒé€²æ¯›é«®ç”Ÿé•·
   - Milrinone ä½œç‚º PDE3 æŠ‘åˆ¶åŠ‘ç†è«–ä¸Šå¯èƒ½æœ‰é¡ä¼¼ä½œç”¨
   - ä½†ç¼ºä¹ç›´æ¥è­‰æ“š

2. **é ­ç—›éšœç¤™**ï¼ˆTxGNN Score: 0.9946ï¼‰
   - Milrinone å…·æœ‰è¡€ç®¡æ“´å¼µä½œç”¨
   - å·²æœ‰ç—…ä¾‹å ±å‘Šé¡¯ç¤ºå‹•è„ˆå…§ Milrinone å¯ç”¨æ–¼æ²»ç™‚å¯é€†æ€§è…¦è¡€ç®¡æ”¶ç¸®ç—‡å€™ç¾¤ï¼ˆRCVSï¼‰
   - é€éè§£é™¤è…¦è¡€ç®¡ç—™æ”£ä¾†ç·©è§£é ­ç—›

3. **å……è¡€æ€§å¿ƒè¡°ç«­**ï¼ˆTxGNN Score: 0.9945ï¼‰
   - æ­¤ç‚ºåŸæ ¸å‡†é©æ‡‰ç—‡ï¼Œæœ‰è±å¯Œè‡¨åºŠè©¦é©—è­‰æ“š

### è‡¨åºŠè©¦é©—

| ç–¾ç—… | è‡¨åºŠè©¦é©—æ•¸é‡ | æœ€é«˜æœŸåˆ¥ | è­‰æ“šç­‰ç´š |
|------|-------------|---------|---------|
| é ­ç—›éšœç¤™ | 1 | N/Aï¼ˆè§€å¯Ÿæ€§ï¼‰ | L3 |
| å……è¡€æ€§å¿ƒè¡°ç«­ | 30+ | Phase 4 | L1 |
| ç¦¿é«®ç—‡ | 0 | - | L5 |

### é‡é»è‡¨åºŠè©¦é©—ï¼ˆå¿ƒè¡°ç«­ç›¸é—œï¼‰

| NCT ID | æ¨™é¡Œ | æœŸåˆ¥ | ç‹€æ…‹ | åœ‹å®¶ |
|--------|------|------|------|------|
| NCT02098629 | Milrinone èˆ‡ Esmolol ä½µç”¨æ–¼æ€¥æ€§å¿ƒè‚Œæ¢—å¡ | Phase 2 | å·²å®Œæˆ | æ–°åŠ å¡ |
| NCT07186062 | Levosimendan vs Dobutamine vs Milrinone æ¯”è¼ƒ | N/A | å·²å®Œæˆ | åŸƒåŠ |
| NCT04718350 | éœè„ˆ Levosimendan vs å¸å…¥ Milrinone æ¯”è¼ƒ | N/A | å·²å®Œæˆ | å¸Œè‡˜ |

### ç›¸é—œæ–‡ç»

### é ­ç—›éšœç¤™ï¼ˆå¯é€†æ€§è…¦è¡€ç®¡æ”¶ç¸®ç—‡å€™ç¾¤ï¼‰

| PMID | æ¨™é¡Œ | å¹´ä»½ | é¡å‹ | è­‰æ“šç­‰ç´š |
|------|------|------|------|---------|
| 34784343 | Reversible Cerebral Vasoconstriction Syndrome in Eclampsia Responding to Milrinone | 2021 | ç—…ä¾‹å ±å‘Š | L3 |
| 25440342 | Novel approach to diagnose reversible cerebral vasoconstriction syndrome | 2015 | ç—…ä¾‹ç³»åˆ— | L3 |
| 18647181 | Intra-arterial milrinone for reversible cerebral vasoconstriction syndrome | 2009 | ç—…ä¾‹å ±å‘Š | L3 |

**é—œéµç™¼ç¾**ï¼š
- å¤šç¯‡ç—…ä¾‹å ±å‘Šé¡¯ç¤ºå‹•è„ˆå…§ Milrinone å¯å¿«é€Ÿæ”¹å–„ RCVS ç›¸é—œçš„è…¦è¡€ç®¡ç—™æ”£å’Œç¥ç¶“ç—‡ç‹€
- ç‰¹åˆ¥é©ç”¨æ–¼éˆ£é›¢å­é€šé“é˜»æ–·åŠ‘æ²»ç™‚ç„¡æ•ˆçš„ç—…ä¾‹
- ä½œç‚º PDE æŠ‘åˆ¶åŠ‘ï¼Œå¯æœ‰æ•ˆé¬†å¼›è¡€ç®¡å¹³æ»‘è‚Œ

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. hypotrichosis simplex of the scalp</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.90%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.90%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. congenital hypotrichosis milia</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.89%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.89%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. diffuse alopecia areata</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.88%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.88%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. headache disorder</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.46%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.46%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. congestive heart failure</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.45%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.45%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. migraine disorder</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.45%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.45%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. migraine with brainstem aura</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.38%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.38%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">9. trigeminal autonomic cephalalgia</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.25%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.25%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">10. acute pulmonary heart disease</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.19%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.19%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰å­—è™Ÿ | å•†å“å | åŠ‘å‹ | è¨±å¯è­‰æŒæœ‰è€… | ç‹€æ…‹ |
|-----------|--------|------|-------------|------|
| ï¼ˆå¾…ç¢ºèªï¼‰ | ç±³åŠ›å¿ƒæ³¨å°„åŠ‘0.2æ¯«å…‹/æ¯«å‡ | æ³¨å°„åŠ‘ | ï¼ˆå¾…ç¢ºèªï¼‰ | æœ‰æ•ˆ |

**é©æ‡‰ç—‡**ï¼šå……è¡€æ€§å¿ƒè¡°ç«­çš„çŸ­æœŸç™‚æ³•ã€‚éœ€åœ¨æœ‰é©ç•¶å¿ƒé›»åœ–ç›£æ¸¬è¨­å‚™çš„ç’°å¢ƒä¸‹ä½¿ç”¨ã€‚

---

## å®‰å…¨æ€§è€ƒé‡

### ä½¿ç”¨æ³¨æ„äº‹é …

1. **å¿ƒå¾‹ä¸æ•´é¢¨éšª**
   - å¯èƒ½å¼•èµ·å±åŠç”Ÿå‘½çš„å®¤æ€§å¿ƒå¾‹ä¸æ•´
   - éœ€æŒçºŒå¿ƒé›»åœ–ç›£æ¸¬

2. **ä½¿ç”¨é™åˆ¶**
   - ç›®å‰ç„¡ä½¿ç”¨è¶…é 48 å°æ™‚çš„å°ç…§è©¦é©—ç¶“é©—
   - å»ºè­°åƒ…ä½œç‚ºçŸ­æœŸç™‚æ³•

3. **è—¥ç‰©äº¤äº’ä½œç”¨**
   - å¸¸èˆ‡ digoxin å’Œåˆ©å°¿åŠ‘ä½µç”¨
   - èˆ‡å…¶ä»–å¼·å¿ƒè—¥ç‰©ä½µç”¨æ™‚éœ€è¬¹æ…

### çµ¦è—¥é€”å¾‘è€ƒé‡

- **éœè„ˆæ³¨å°„**ï¼šå¿ƒè¡°ç«­æ¨™æº–çµ¦è—¥æ–¹å¼
- **å‹•è„ˆå…§æ³¨å°„**ï¼šRCVS æ²»ç™‚çš„ç ”ç©¶çµ¦è—¥æ–¹å¼ï¼Œéœ€å°ˆæ¥­ä»‹å…¥è¨­å‚™
- **å¸å…¥çµ¦è—¥**ï¼šè‚ºé«˜å£“æ²»ç™‚çš„ç ”ç©¶çµ¦è—¥æ–¹å¼

---


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**è‚è‡Ÿç–¾ç—… (Liver Diseases)** ğŸŸ¡ Moderate
- The use of inamrinone (former amrinone) has been associated with hepatotoxicity, manifested as marked alterations in liver function tests and clinical symptoms suggestive of idiosyncratic hypersensitivity.  This especially after long-term use.  Thera...

**ä½è¡€å£“ (Hypotension)** ğŸŸ¡ Moderate
- The use of amrinone or milrinone is associated with a fall in blood pressure.  Some patients have required correction by intravenous infusion of plasma.  Therapy with amrinone or milrinone should be administered cautiously in hypotensive patients.  M...

**Thrombocytopenia** ğŸŸ¡ Moderate
- The use of amrinone, and infrequently, milrinone, can cause thrombocytopenia.  This appears to be dose-dependent and usually occurs during prolonged therapy.  Therapy with amrinone and milrinone should be administered cautiously in patients with thro...

**Arrhythmias, Cardiac** ğŸŸ¢ Minor
- The use of milrinone both intravenously and orally has been associated with increased frequency of ventricular arrhythmias, including nonsustained ventricular tachycardia.  Long-term oral use has been associated with an increased risk of sudden death...

**Heart Valve Diseases** ğŸŸ¢ Minor
- Milrinone should not be used in patients with severe obstructive aortic or pulmonic valvular disease in lieu of surgical relief of the obstruction.  Like other inotropic agents, it may aggravate outflow tract obstruction in hypertrophic subaortic ste...

*å¦æœ‰ 1 é …ç–¾ç—…æ³¨æ„äº‹é …ï¼Œè©³è¦‹ [DDInter 2.0](https://ddinter2.scbdd.com/)*

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

### è©•ä¼°çµè«–

| é æ¸¬é©æ‡‰ç—‡ | è­‰æ“šç­‰ç´š | è‡¨åºŠè½‰è­¯å¯è¡Œæ€§ | å»ºè­°å„ªå…ˆé †åº |
|-----------|---------|---------------|-------------|
| é ­ç—›éšœç¤™ï¼ˆRCVSï¼‰ | L3 | ä¸­ç­‰ | å»ºè­°é€²ä¸€æ­¥ç ”ç©¶ |
| ç¦¿é«®ç—‡ | L5 | ä½ | ä¸å»ºè­°å„ªå…ˆé–‹ç™¼ |
| å¿ƒè¡°ç«­ | L1 | é«˜ï¼ˆå·²æ ¸å‡†ï¼‰ | ä¸é©ç”¨ |

### å»ºè­°

1. **å¯é€†æ€§è…¦è¡€ç®¡æ”¶ç¸®ç—‡å€™ç¾¤ï¼ˆRCVSï¼‰**
   - ç›®å‰å·²æœ‰å¤šç¯‡ç—…ä¾‹å ±å‘Šæ”¯æŒå‹•è„ˆå…§ Milrinone çš„ç™‚æ•ˆ
   - å»ºè­°è¨­è¨ˆå‰ç»æ€§ç ”ç©¶è©•ä¼°å®‰å…¨æ€§å’Œæœ‰æ•ˆæ€§
   - å¯è€ƒæ…®ä½œç‚ºéˆ£é›¢å­é€šé“é˜»æ–·åŠ‘ç„¡æ•ˆæ™‚çš„æ•‘æ´æ²»ç™‚

2. **ç¦¿é«®ç—‡**
   - é›–ç„¶ PDE æŠ‘åˆ¶åŠ‘ç†è«–ä¸Šå¯èƒ½æœ‰æ•ˆ
   - ä½† Milrinone ç‚ºæ³¨å°„åŠ‘å‹ï¼Œä¸é©åˆå±€éƒ¨å¤–ç”¨æ²»ç™‚ç¦¿é«®
   - ä¸å»ºè­°é€²ä¸€æ­¥é–‹ç™¼

### å¾ŒçºŒè¡Œå‹•

- [x] ç¢ºèªé ­ç—›éšœç¤™æ–‡ç»è­‰æ“šï¼ˆå·²æœ‰ 3 ç¯‡ç—…ä¾‹å ±å‘Šï¼‰
- [ ] ç›£æ¸¬ RCVS æ²»ç™‚çš„æ–°è‡¨åºŠè©¦é©—
- [ ] è©•ä¼°æ˜¯å¦æœ‰å¯èƒ½é–‹ç™¼å±€éƒ¨å¤–ç”¨åŠ‘å‹ç”¨æ–¼ç¦¿é«®ï¼ˆå¯è¡Œæ€§ä½ï¼‰

---

*å ±å‘Šç”¢ç”Ÿæ—¥æœŸï¼š2026-02-11*
*è³‡æ–™ä¾†æºï¼šTxGNN é æ¸¬ã€ClinicalTrials.govã€PubMedã€å°ç£ FDA*


---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Nitrofurantoin]({{ "/drugs/nitrofurantoin/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Trabectedin]({{ "/drugs/trabectedin/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Zanubrutinib]({{ "/drugs/zanubrutinib/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Remdesivir]({{ "/drugs/remdesivir/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Cladribine]({{ "/drugs/cladribine/" | relative_url }}) - è­‰æ“šç­‰ç´š L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Milrinoneè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/milrinone/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_milrinone,
  title = {Milrinoneè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/milrinone/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
